GLP-1 Peptides in Type 1 Diabetes: Off-Label Use and Evidence

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

GLP-1 receptor agonists are increasingly used off-label in type 1 diabetes to improve glycemic control, reduce insulin requirements, and promote weight management, with growing evidence supporting their adjunctive role.

Type 1 diabetes (T1D) is characterized by autoimmune destruction of pancreatic beta cells, leading to absolute insulin deficiency. While exogenous insulin remains the cornerstone of T1D management, achieving optimal glycemic control without increasing hypoglycemia risk or causing weight gain is a persistent challenge. Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs), approved for type 2 diabetes (T2D), are increasingly being used off-label in T1D due to their pleiotropic effects that complement insulin therapy.

Rationale for Off-Label Use in T1D

The rationale for using GLP-1 RAs in T1D stems from their physiological actions, which can address several unmet needs in T1D management:

Glucagon Suppression: GLP-1 RAs suppress glucagon secretion, particularly post-prandially, which helps to reduce hepatic glucose production and improve post-meal glucose excursions [1]. This is beneficial in T1D where alpha-cell dysregulation leads to inappropriate glucagon secretion.

Delayed Gastric Emptying: By slowing gastric emptying, GLP-1 RAs can flatten post-prandial glucose peaks, making it easier to match insulin doses to carbohydrate intake and reducing glucose variability [1].

Weight Management: Many individuals with T1D, especially those on intensive insulin regimens, experience weight gain. GLP-1 RAs promote satiety and reduce appetite, leading to weight loss or stabilization, which can improve insulin sensitivity and overall metabolic health [2].

Insulin Sparing Effect: By improving glycemic control and insulin sensitivity, GLP-1 RAs can potentially reduce total daily insulin requirements, thereby lowering the risk of hypoglycemia and improving patient convenience [2].

Beta-Cell Preservation (Theoretical): While not directly applicable to established T1D, some early research in new-onset T1D suggests GLP-1 RAs might have a role in preserving residual beta-cell function, though this remains an area of active investigation [3].

Improved Glycemic Control: Studies have shown that GLP-1 RAs, when added to insulin therapy, can lead to modest but significant reductions in HbA1c (typically 0.3-0.6%) without increasing the risk of severe hypoglycemia [4]. This improvement is often accompanied by reduced glucose variability.

Weight Loss: Consistent weight loss (typically 2-5 kg) has been observed in T1D patients treated with GLP-1 RAs, which is a significant benefit for those struggling with insulin-induced weight gain [4].

Reduced Insulin Dose: Patients often experience a reduction in total daily insulin dose, particularly bolus insulin, contributing to better glycemic control and potentially fewer hypoglycemic events [4].

Cardiovascular Benefits: Although not as extensively studied as in T2D, the cardiovascular benefits of GLP-1 RAs (e.g., blood pressure reduction, lipid profile improvement) may also extend to individuals with T1D, given their shared cardiovascular risk factors [5].

Diabetic Ketoacidosis (DKA) Risk: There is a theoretical concern that delayed gastric emptying and reduced insulin doses could increase the risk of DKA, especially if patients reduce insulin too aggressively or during periods of illness. Patients must be educated on sick day rules and never to discontinue insulin [6].

Gastrointestinal Side Effects: Nausea, vomiting, and diarrhea are common side effects, particularly during initiation and dose escalation, which can impact adherence.

Pancreatitis and Thyroid C-cell Tumors: While rare, these risks, observed in T2D populations, are also a consideration, though data in T1D are limited.

Cost and Access: GLP-1 RAs are expensive, and off-label use may not be covered by insurance, posing a significant barrier to access.

Lack of Regulatory Approval: The absence of regulatory approval means that comprehensive safety and efficacy data specifically for T1D are still accumulating, and clinicians must exercise caution and informed consent.

Conclusion

GLP-1 RAs offer a compelling adjunctive therapy for individuals with type 1 diabetes, addressing challenges such as post-prandial hyperglycemia, weight gain, and insulin requirements. While promising, their off-label use necessitates careful patient selection, thorough education, close monitoring for adverse events (especially DKA), and an understanding of the current evidence base. As research continues, GLP-1 RAs may become a more formally recognized component of comprehensive T1D management, moving beyond their current off-label status.